Scancell Share Discussion Threads

[1knocker] 26/7/2023 10:15

What is your interest here, Tyke? You do not seem much enamoured of this as an investment. Presumably you are here because you want a new board to post on where your track record is not known, and where there are unlikely to be technical analysts to point out the deficiencies in your application of EW theory?

PS Still waiting for your exciting inside account of your RMM and Mode debacles!

[ivyspivey] 26/7/2023 08:41

Seagull’s indeed.
So tyke either a Brighton fan or knows the connection between “ Seagulls” and Leeds.
GLA

[marcusl2] 26/7/2023 08:09

Cleanerworld



Clatterbridge has new cancer Trial Recruitment film ,Today 07:27
Morning Firstly Roses has your post disappeared questioning the share drop ? on just 44K

I find this very positive on investment into trial recruitment

New video for cancer trials at the Clatterbridge -

Looks like the same animation designers as Modify Trial , the Modify overview is interesting

hxxps://modi-1-study.digitrial.com

The ModiFY study: Overview

The ModiFY clinical trial, is being conducted in hospitals across the UK, so that researchers can assess whether the Modi-1 vaccine when given to patients with specific cancer types:

1. Is safe at different doses

2. Can trigger the immune system to fight cancer

3. Is effective at shrinking tumours

The clinical trial is recruiting patients with the following advanced cancer types:

1. (HPV negative) Head and Neck Cancer

2. Renal Cell Cancer

3. Triple Negative Breast Cancer

The study is also recruiting patients with Head and Neck Cancer that are planning to undergo surgery.

The short video below provides more information about the study.

[2tyke] 26/7/2023 07:15

Yes seagulls loggy..
It's grim up north...dark, grey and it smells a bit.........................................................
Some clown on LSE asking who's right, the market or LTH's ? Lol.
That's a really tough one !!!
Still, after 15 years of failure.,.they'll no doubt think that they are.
Let me guess.....manipulation.....off-loading...options.....under the radar.
Take your pick really innit ?

[thelogman] 25/7/2023 18:59

OK seagulls, 😀👍

[2tyke] 25/7/2023 18:57

Yes we have loggy....

I'm a seagull myself...
SEAGULLS !!!!

[thelogman] 25/7/2023 18:41

2tyke, you obviously have not come across me on sclp. Have been following, trading scancell for years and still have a small free holding whilst made decent gains for me. Now the question is have we made money out of scancell or not? I will leave it at that. WE ARE LUFC.

[golcheja] 25/7/2023 17:34

Yahoo .why Scancell share price is climbing ?
Claiming from 8p to 11p and today collapsing back to 10…I guess that explains.

[2tyke] 25/7/2023 14:46

Panama,
No need to look for 'reasons'.
The only thing that matters to the traders that 'control' the price is profit and loss.
That's precisely why they do exactly the same thing at similar points in time.
No story or reasoning necessary.

[panama7] 25/7/2023 14:22

I wonder if the fall today has anything to do with the release of 15,000 pages of the Moderna trial results. Maybe investors are getting twitchy about the whole vaccine industry. I did warn about this 2 years ago. The Truth is out there.

[2tyke] 25/7/2023 14:03

logman,
Of course the posts on here are all codswallop.
Comments like "when the market wakes up to what Scancell have'...lol
The market is fully awake !. It's the fundamentalists who are asleep at the wheel ...as usual.
A price series follows a set pattern. That's why the 'value' merchants call it wrong ...and the elliotticians call things right !

[the real lozan] 25/7/2023 10:12

REALITY =
Today 25 JULY, we are 'basking' in/at the mid day high summer, here in S W France,.. temperature of =
17.7 C
Which may not be quite the 'story' that certain 'outlets' would have folks believe.
There are MANY things that are, in reality,that certain 'outlets' would have folks believe.

[marcusl2] 25/7/2023 07:51

"Axing enapotamab vedotin will free up resources for Genmab’s other prospects, said CEO Jan van de Winkel, Ph.D., in the statement.


SC129: specific for the sialyl-di-Lewisa glycan, a target for pancreatic cancer

Scancell can earn up to a maximum US$624mln if Genmab develops and commercialises all modalities plus royalties on net sales.

[thelogman] 24/7/2023 18:02

Posts on here are total codswallop to me all I know share price was 27pish now 11pish, that's why you should trade not sit. Must admit I never sold in the mid twenties as thought to risky at the time so I held till below 20 then sold, then said under 14p this is going, did not expect it to go this low though. LEEDS first game is against Cardiff, will have 18 deck ready.

[marcusl2] 24/7/2023 14:45

The cancer vaccine helped the CAR-T cell therapy attack tumor cells.

[marcusl2] 24/7/2023 12:39

GlyMab
(SC88)
WO 2015/063500 A1 2013-11-01 Glycans As Functional Cancer Targets And
Antibodies Thereto
Granted
Patent
ACTIVE

Maybe the next deal ?

Possibly Avidimab or SC2811.


Google Vulpes Investment Management - Vulpes, opportunities then Vulpes Life Sciences
(click on Scancell Report: Multiple Arrows in its Quiver)

SC88: specific for the Lewisacx glycan, a target for colorectal cancer;
SC27: specific for the Lewisy glycan, a target for gastric cancer
SC2811: specific for SSEA4 on human and mouse T cells with stem-like properties – a target for any solid tumour

[888icb] 24/7/2023 11:35

I accessed the report via a link provided by a poster on lse. The report doesn’t have a date I can find however the shareholder breakdown information in the report from Bloomberg is dated February 2023, so it’s recent.

[plasybryn] 24/7/2023 11:00

What date was that please 8881CB?

[888icb] 23/7/2023 12:52

Vulpes Investment Appraisal
This is their comment on Valuation:

“ Valuation: We view the current share price as derisory; reflective of poor market sentiment for biotech stocks and the early-stage nature of the business, with management too focused on the science, rather than medium- and long-term commercial aspects. If Modi 1 were successful across all 4 tumour indications, it could deliver c.$2.8bn in aggregate profits (present – value adjusted, but not probability adjusted) based on our (Vulpes) estimates. Even adjusted with a 10% PoS (probability of success) that would imply a market value of c.$280m – a c.62% uptick vis-à-vis the current market cap of around $173m. And this is from a single asset. Modi-2, which addresses other solid tumours like colorectal cancer, non-small cell lung cancer, and prostate cancer, among others, could (if successful across all indications) deliver c.$2.3bn in profits (our estimates; present – value adjusted, but not probability adjusted). Even adjusted with a 7% PoS that would imply a market value of c.$160m – which again equates to almost the entire current market capitalisation of the company.”

[marcusl2] 23/7/2023 12:29

True value of our vaccine is probably in combination with checkpoint inhibitors

Additionally, Scancell has recruited a fourth cohort of three patients receiving full dose Modi-1 in combination with the checkpoint inhibitor nivolumab. Subject to a safety committee review meeting scheduled to take place in August, this cohort will be expanded to 21 patients in both head and neck and renal cancer. Preliminary
topline data from these cohorts is expected to be reported in 2024.

[marcusl2] 23/7/2023 12:26

When the market starts to understand what Scancell has....

44% disease control rate (DCR) in ovarian cancer patients in ModiFY monotherapy trial

Scib plus doublet looking very good

Avidimab

The Glymabs

“I am very encouraged by the data we have seen so far from both the SCOPE trial with SCIB1 and the ModiFY trial with Modi-1, which support the decision to sharpen our focus on these two assets” said Scancell CEO Lindy Durrant.

Additionally, I am pleased to see that Modi-1 is having an effect on disease control in ovarian cancer in these very heavily pre-treated patients, although we believe the
true value of our vaccine is probably in combination with checkpoint inhibitors.

Dr David Pinato, Principal Investigator at Imperial College, commented: “Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in patients who have exhausted most treatment options is very encouraging”.

[marcusl2] 23/7/2023 12:21

Roche’s Genentech paid BioNTech $310 million in upfront and near-term milestones in 2016 to gain access to mRNA-based personalized cancer vaccines

[panama7] 23/7/2023 10:35

Knocker you left out the 800bn they printed to save us all from a virus with a 99.997% survival rate although to be fair Starmer would have printed an extra 200bn to save us from the same virus and locked us down for even longer.